Tokyo company acquires KC Specialty Therapeutics

Hungry for expansion opportunities in the U.S., a Tokyo-based company is acquiring the assets of KC Specialty Therapeutics in Kansas City, Kan.   KC Specialty, a subsidiary of Statson Pharmaceuticals, will retain its local operations. Financial details were not disclosed.  For Tokyo's Kangen Pharmaceuticals, the deal offers growth opportunity in the U.S. and Japan and broadens its network of affiliates and alliances in Asia and Europe, Kangen President Norihiro Hirota said in a release.  "This…
Source: bizjournals.com Health Care News Headlines - Category: Health Management Authors: Source Type: news